1308 Miscellaneous drug categories
Reactions may be
common
, uncommon,
life-threatening
, or
commonandlife-threatening.
Contraindications
Contraindicated in individuals with known
hypersensitivity to the preparation or
a history of serious hypersensitivity to
iopamidol or iodine-containing contrast
media, and in those with thyrotoxicosis or
decompensated cardiac insufficiency.
care considerations
• Closely monitor individual for devel
opment of anaphylactic reaction. Ensure
emergency management equipment is
available and in correct working order.
• Monitor vital signs and renal function
closely following procedure.
• Ensure the person is well-hydrated before
and after the procedure to avoid contrast-
induced nephropathy.
• Assess mental status.
• Ensure safety if the person is light-headed.
• Thyroid function testsmay be reduced for
up to several weeks.
Patient teaching
• Advisepersontoreportanyadverseeffects.
• Advise person to take care when standing
up or getting out of bed due to potential
dizziness.
iopromide
Ultravist
Pregnancy risk category B2
Use in sport: Permitted
Available forms
Solution for injection:
0.499 g iopromide/mL
(240 mg iodine/mL) in 50 mL; 0.623 g
iopromide/mL (300 mg iodine/mL) in 20 mL,
50 mL, 75 mL, 100 mL, 150 mL; 0.769 g
iopromide/mL (370 mg iodine/mL) in 20 mL,
30 mL, 50 mL, 75 mL, 100 mL, 200 mL
Indications & dosages
➤
X-rayorCTcontrastmedium—
Adults:
Individualised according to indi
vidual factors and nature of X-ray or CT scan.
Action
Non-ionic iodinated radiographic contrast
medium for angiographic and urographic
examinations.
Route Onset
Peak
Duration
IV
Immediate Unknown 24 hrs
Adverse reactions
CNS:
convulsions
, dizziness, dysgeusia,
headache, hypaesthesia, restlessness, palpi
tations, paraesthesia, somnolence, syncope,
vasodilation, vasovagal reactions.
CV:
arrhythmia, bradycardia, chest pain,
cardiac arrest
,
circulatory collapse
, hyper
tension, hypotension,
lossofconsciousness
,
myocardial ischaemia
,
shock
, vasodilation,
thromboembolic events
.
Endocrine:
thyroid disorder,
thyrotoxic
crisis
.
ENT:
nasal congestion, rhinitis, sneezing.
Eye:
altered vision, blurred vision.
GI:
abdominal pain, anorexia, diarrhoea,
dysphagia, nausea, vomiting.
GU:
acute renal failure
, altered renal func
tion, incontinence,
contrast medium–
induced nephrotoxicity
, urinary retention.
Musculoskeletal:
asthenia, compartment
syndrome, muscle cramps, myalgia, myop
athy.
Psychiatric:
anxiety, confusion.
Respiratory:
asthma,
bronchospasm
,
dyspnoea,
laryngeal oedema
, pharyngitis,
pulmonary oedema, respiratory distress.
Skin:
angio-oedema
,clamminess,erythema,
flushing, injection site pain, itching, pruritus,
rash, sweating, urticaria.
Other:
anaphylactic reaction
, fever, hyper
sensitivityreactions, iodism,malaise,pyrexia,
rigors.
Interactions
Drug-drug.
Metformin/biguanides:
Potential
transient impairment of renal function
with possible lactic acidosis. Should be
discontinued 48 hours prior to and for 48
hours after procedure.
